Deepesh Lad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Deepesh Lad has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
Alka Khadwal
58 shared publicationsGaurav Prakash
Department of Clinical Haematology and Medical Oncology, Post Graduate Institute of Medical Education & Research, Chandigarh, India
54 shared publicationsPankaj Malhotra
43 shared publications- Pankaj Malhotra
Department of Clinical Hematology and Medical Oncology Postgraduate Institute of Medical Education and Research Chandigarh India
42 shared publications Subhash Varma
Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
39 shared publicationsNeelam Varma
Department of Hematology Postgraduate Institute of Medical Education and Research Chandigarh India
32 shared publications
Latest Publications
- 2 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Randomized Controlled Trial Comparing Lactoferrin+Iron with Iron Alone for Iron Deficiency Anemia in CKD
Key Points: Lactoferrin+iron significantly improved hemoglobin and iron indices versus iron alone in CKD patients with iron deficiency anemia. Lactoferrin reduced hepcidin and inflammatory markers, suggesting improved iron utilization using anti-inflammatory mechanisms. Three patients with iron deficiency anemia had elevated inflammatory markers, higher among patients with CKD on dialysis than those not on dialysis. Background: Lactoferrin, a multifunctional iron-binding glycoprotein with anti-inflammatory properties, is reported to be effective in anemia in pregnant women and patients with malignancy but has not been tested elaborately in CKD. Methods: In this randomized, open-label trial, 185 patients (intention-to-treat) with iron-deficiency anemia (hemoglobin [Hb] <10 g/dl, transferrin saturation <20%) were enrolled: 90 with patients with CKD not on dialysis (CKD-ND) and 95 with dialysis-dependent CKD (patients with CKD on dialysis [CKD-5D]). Patients were randomized to receive either oral iron (30 mg/d liposomal iron) or oral iron+lactoferrin (100 mg twice daily) for 3 months. The primary outcome was change in Hb. Secondary outcomes included iron indices and inflammatory markers (C-reactive protein, IL-6, erythrocyte sedimentation rate, and hepcidin). Results: In the intention-to-treat analysis, lactoferrin+iron resulted in significantly greater improvements in Hb and iron parameters than iron alone in both patients with CKD-ND and those with CKD-5D. Mean Hb increased by 1.95±1.19 versus 1.33±0.86 g/dl in patients with CKD-ND and by 1.73±0.96 versus 1.11±0.93 g/dl in patients with CKD-5D receiving lactoferrin+iron and iron alone, respectively. Improvements in iron indices were also greater with add-on lactoferrin treatment. Mean difference in hepcidin levels were −20.24±15.99 versus −16.03±40.65 ng/dl in patients with CKD-ND and −15.29±8.73 versus −20.99±20.16 ng/dl in patients with CKD-5D treated with lactoferrin+iron and iron alone, respectively. Conclusions: Among patients with CKD-associated anemia, adjunctive lactoferrin therapy improved Hb and iron parameters compared with oral iron alone in both non–dialysis-dependent and dialysis-dependent patients. Lactoferrin was also associated with modest improvements in inflammatory status, although effects on individual inflammatory markers were inconsistent. These findings suggest that lactoferrin may be a useful adjunct to oral iron therapy for the management of anemia in CKD, especially in resource-limited settings. Clinical Trial registry name and registration number: Clinical Trials Registry of India, CTRI/2020/04/024746.
- 2 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Randomized Controlled Trial Comparing Lactoferrin+Iron with Iron Alone for Iron Deficiency Anemia in CKD
Key Points: Lactoferrin+iron significantly improved hemoglobin and iron indices versus iron alone in CKD patients with iron deficiency anemia. Lactoferrin reduced hepcidin and inflammatory markers, suggesting improved iron utilization using anti-inflammatory mechanisms. Three patients with iron deficiency anemia had elevated inflammatory markers, higher among patients with CKD on dialysis than those not on dialysis. Background: Lactoferrin, a multifunctional iron-binding glycoprotein with anti-inflammatory properties, is reported to be effective in anemia in pregnant women and patients with malignancy but has not been tested elaborately in CKD. Methods: In this randomized, open-label trial, 185 patients (intention-to-treat) with iron-deficiency anemia (hemoglobin [Hb] <10 g/dl, transferrin saturation <20%) were enrolled: 90 with patients with CKD not on dialysis (CKD-ND) and 95 with dialysis-dependent CKD (patients with CKD on dialysis [CKD-5D]). Patients were randomized to receive either oral iron (30 mg/d liposomal iron) or oral iron+lactoferrin (100 mg twice daily) for 3 months. The primary outcome was change in Hb. Secondary outcomes included iron indices and inflammatory markers (C-reactive protein, IL-6, erythrocyte sedimentation rate, and hepcidin). Results: In the intention-to-treat analysis, lactoferrin+iron resulted in significantly greater improvements in Hb and iron parameters than iron alone in both patients with CKD-ND and those with CKD-5D. Mean Hb increased by 1.95±1.19 versus 1.33±0.86 g/dl in patients with CKD-ND and by 1.73±0.96 versus 1.11±0.93 g/dl in patients with CKD-5D receiving lactoferrin+iron and iron alone, respectively. Improvements in iron indices were also greater with add-on lactoferrin treatment. Mean difference in hepcidin levels were −20.24±15.99 versus −16.03±40.65 ng/dl in patients with CKD-ND and −15.29±8.73 versus −20.99±20.16 ng/dl in patients with CKD-5D treated with lactoferrin+iron and iron alone, respectively. Conclusions: Among patients with CKD-associated anemia, adjunctive lactoferrin therapy improved Hb and iron parameters compared with oral iron alone in both non–dialysis-dependent and dialysis-dependent patients. Lactoferrin was also associated with modest improvements in inflammatory status, although effects on individual inflammatory markers were inconsistent. These findings suggest that lactoferrin may be a useful adjunct to oral iron therapy for the management of anemia in CKD, especially in resource-limited settings. Clinical Trial registry name and registration number: Clinical Trials Registry of India, CTRI/2020/04/024746.
- 14 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (9) , 1079.e1-1079.e3
Prevalence of Clinically Significant Viral and Bacterial Enteric Pathogens Among Indian Hematopoietic Stem Cell Transplant Recipients and Allogeneic Donors
- 14 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (9) , 1079.e1-1079.e3
Prevalence of Clinically Significant Viral and Bacterial Enteric Pathogens Among Indian Hematopoietic Stem Cell Transplant Recipients and Allogeneic Donors
- 7 April 2026
- Published by Wiley in Nephrology
- Vol. 31 (4) , e70201
Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study
Aim: Post‐renal transplant anaemia significantly impacts patient outcomes and quality of life. The only option available until recently was erythropoietin (EPO) that requires intravenous or subcutaneous injection. New class of drugs that are hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHI) (desidustat) have become available and there is scarce data on their use in kidney transplant recipients (KTRs). Methods: This was a prospective observational study which included 58 renal transplant recipients with anaemia (Hb < 10 g/dL) who were started on either oral HIF‐PHI in the form of desidustat ( n = 30) or EPO ( n = 28) based on nephrologist discretion. Adult KTRs with a haemoglobin (Hb) level of less than 10 g/dL were included. Patients with acute graft dysfunction, bleeding and primary haematological diseases were excluded. Baseline clinical characteristics were recorded. Primary outcomes were change in Hb at 8 weeks in the two groups. Secondary outcomes included inflammatory markers (CRP, ESR), iron indices and safety. Results: Both desidustat and erythropoietin groups showed significant improvement in Hb from baseline to 2 months (desidustat: 8.69 ± 0.86 to 9.89 ± 0.92 g/dL; EPO: 8.54 ± 0.73 to 9.55 ± 0.71 g/dL; p > 0.05). No significant differences were observed in inflammatory markers or iron indices. Both treatments were well‐tolerated, with no reported adverse events. Conclusion: Treatment with desidustat resulted in improvement in haemoglobin levels with acceptable tolerability over short‐term follow‐up similar to erythropoietin. The convenience of oral administration supports its potential role as a patient‐centred option for anaemia management following kidney transplantation.
- 7 April 2026
- Published by Wiley in Nephrology
- Vol. 31 (4) , e70201
Efficacy and Safety of Desidustat Versus Erythropoietin in Post Kidney Transplant Anaemia: A Prospective Observational Study
Aim: Post‐renal transplant anaemia significantly impacts patient outcomes and quality of life. The only option available until recently was erythropoietin (EPO) that requires intravenous or subcutaneous injection. New class of drugs that are hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHI) (desidustat) have become available and there is scarce data on their use in kidney transplant recipients (KTRs). Methods: This was a prospective observational study which included 58 renal transplant recipients with anaemia (Hb < 10 g/dL) who were started on either oral HIF‐PHI in the form of desidustat ( n = 30) or EPO ( n = 28) based on nephrologist discretion. Adult KTRs with a haemoglobin (Hb) level of less than 10 g/dL were included. Patients with acute graft dysfunction, bleeding and primary haematological diseases were excluded. Baseline clinical characteristics were recorded. Primary outcomes were change in Hb at 8 weeks in the two groups. Secondary outcomes included inflammatory markers (CRP, ESR), iron indices and safety. Results: Both desidustat and erythropoietin groups showed significant improvement in Hb from baseline to 2 months (desidustat: 8.69 ± 0.86 to 9.89 ± 0.92 g/dL; EPO: 8.54 ± 0.73 to 9.55 ± 0.71 g/dL; p > 0.05). No significant differences were observed in inflammatory markers or iron indices. Both treatments were well‐tolerated, with no reported adverse events. Conclusion: Treatment with desidustat resulted in improvement in haemoglobin levels with acceptable tolerability over short‐term follow‐up similar to erythropoietin. The convenience of oral administration supports its potential role as a patient‐centred option for anaemia management following kidney transplantation.
- 1 April 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (8) , 1824-1828
Lenalidomide exposure duration and drug holidays do not affect stem cell mobilisation with plerixafor and G-CSF in multiple myeloma
- 1 April 2026
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 67 (8) , 1824-1828
Lenalidomide exposure duration and drug holidays do not affect stem cell mobilisation with plerixafor and G-CSF in multiple myeloma
- Open Access
- 13 February 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1
Correction: A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
- 13 February 2025
- Published by Springer Nature in Blood Cancer Journal
- Vol. 15 (1) , 1
Open AccessCorrection: A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
- 3 December 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 1-3
Retrieval of Broken Trephine Biopsy Needle in the Sacro-Iliac Joint
- 3 December 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 1-3
Retrieval of Broken Trephine Biopsy Needle in the Sacro-Iliac Joint
- Open Access
- 11 November 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-4
A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
- 11 November 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 1-4
Open AccessA simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma
- 3 November 2024
- Published by Wiley in European Journal of Haematology
- Vol. 114 (2) , 202-212
Maternal and Fetal Outcomes of Aplastic Anemia During Pregnancy and Delivery: Systematic Review and Meta‐Analysis
Background: Little scientific evidence exists on maternal and fetal outcomes in aplastic anemia (AA) during pregnancy.Aim: The review was conducted to assess the maternal and fetal outcomes due to AA during pregnancy.Data Sources: Web of Science, EMBASE, PubMed, Scopus, Cochrane CENTRAL, and registries until May 5, 2024.Study Eligibility Criteria: Studies (prospective, retrospective cohort, cross‐sectional, one arm, survey, follow‐up studies) evaluating AA during pregnancy were searched as per PROSPERO registered protocol (CRD42024506668). Case reports, case series, expert opinion letters, and studies assessing less than or equal to 10 pregnant women were not considered. The primary outcome was the prevalence of preeclampsia in AA pregnancies. The secondary outcomes included spontaneous abortion, preterm premature rupture of membranes, premature rupture of membranes, fetal growth restriction, type of delivery, intrauterine fetal death, maternal and neonatal mortality, and pre and post‐pregnancy remission status comparison.Methods: The quality of research was checked using the New Castle‐Ottawa risk‐of‐bias tool. A meta‐analysis model with a random effect distribution, coupled with meta‐regression, sensitivity analysis, and publication bias assessment, was used in the statistical software R. Standard Equator network study reporting guidelines were followed.Results: Seven (one prospective and six retrospective cohort) studies included patients with confirmed AA diagnosis in 248 pregnancies. The pooled prevalence of preeclampsia was 13% (95% CI, 8%–20%). Heterogeneity was low in the present meta‐analysis (I 2 = 26%). The secondary outcome evaluation showed a pooled prevalence of 5% (95% CI, 3%–11%) for spontaneous abortion, 4% (95% CI, 1%–11%) for preterm premature rupture of membranes, 10% (95% CI, 3%–28%) for premature rupture of membranes, 6% (95% CI, 3%–11%) for fetal growth restriction, 5% (95% CI, 2%–13%) for intrauterine fetal death, 12% (95% CI, 5%–26%) for post‐partum hemorrhage, 74% (95% CI, 45%–91%) for intrapartum transfusion requirement, and 55% (95% CI, 27%–80%) for the cesarean delivery opting. The maternal mortality in pregnancies with AA was 4% (95% CI, 0.01–0.14), whereas neonatal mortality was 7% (95% CI, 0.03–0.18). The odds of AA complete remission were better in pre‐pregnancy than post‐pregnancy (OR = 0.36; 95% CI = 0.08–1.66), although the results remain insignificant. The leave‐one‐out sensitivity analysis did not change the pooled estimates for the primary outcome.Conclusion: A risk of developing preeclampsia was observed in every eighth pregnant woman with an AA diagnosis. AA remission status might worsen after undergoing pregnancy, considering the significant obstetric morbidity and mortality burden.
- 3 November 2024
- Published by Wiley in European Journal of Haematology
- Vol. 114 (2) , 202-212
Maternal and Fetal Outcomes of Aplastic Anemia During Pregnancy and Delivery: Systematic Review and Meta‐Analysis
Background: Little scientific evidence exists on maternal and fetal outcomes in aplastic anemia (AA) during pregnancy.Aim: The review was conducted to assess the maternal and fetal outcomes due to AA during pregnancy.Data Sources: Web of Science, EMBASE, PubMed, Scopus, Cochrane CENTRAL, and registries until May 5, 2024.Study Eligibility Criteria: Studies (prospective, retrospective cohort, cross‐sectional, one arm, survey, follow‐up studies) evaluating AA during pregnancy were searched as per PROSPERO registered protocol (CRD42024506668). Case reports, case series, expert opinion letters, and studies assessing less than or equal to 10 pregnant women were not considered. The primary outcome was the prevalence of preeclampsia in AA pregnancies. The secondary outcomes included spontaneous abortion, preterm premature rupture of membranes, premature rupture of membranes, fetal growth restriction, type of delivery, intrauterine fetal death, maternal and neonatal mortality, and pre and post‐pregnancy remission status comparison.Methods: The quality of research was checked using the New Castle‐Ottawa risk‐of‐bias tool. A meta‐analysis model with a random effect distribution, coupled with meta‐regression, sensitivity analysis, and publication bias assessment, was used in the statistical software R. Standard Equator network study reporting guidelines were followed.Results: Seven (one prospective and six retrospective cohort) studies included patients with confirmed AA diagnosis in 248 pregnancies. The pooled prevalence of preeclampsia was 13% (95% CI, 8%–20%). Heterogeneity was low in the present meta‐analysis (I 2 = 26%). The secondary outcome evaluation showed a pooled prevalence of 5% (95% CI, 3%–11%) for spontaneous abortion, 4% (95% CI, 1%–11%) for preterm premature rupture of membranes, 10% (95% CI, 3%–28%) for premature rupture of membranes, 6% (95% CI, 3%–11%) for fetal growth restriction, 5% (95% CI, 2%–13%) for intrauterine fetal death, 12% (95% CI, 5%–26%) for post‐partum hemorrhage, 74% (95% CI, 45%–91%) for intrapartum transfusion requirement, and 55% (95% CI, 27%–80%) for the cesarean delivery opting. The maternal mortality in pregnancies with AA was 4% (95% CI, 0.01–0.14), whereas neonatal mortality was 7% (95% CI, 0.03–0.18). The odds of AA complete remission were better in pre‐pregnancy than post‐pregnancy (OR = 0.36; 95% CI = 0.08–1.66), although the results remain insignificant. The leave‐one‐out sensitivity analysis did not change the pooled estimates for the primary outcome.Conclusion: A risk of developing preeclampsia was observed in every eighth pregnant woman with an AA diagnosis. AA remission status might worsen after undergoing pregnancy, considering the significant obstetric morbidity and mortality burden.
- 1 July 2024
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (11) , 1675-1690
Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profiles
This study investigates acute myeloid leukemia/lymphoblastic leukemia (AML/ALL) through a 14-year analysis (2009-2022) of 46 autopsied cases (age >12 years). B-ALL was the dominant subtype (34.8%). Liver and spleen were the common sites of active leukemia (63% cases). Symptoms like dyspnea and altered sensorium associated significantly with heart (p = .031) and brain leukostasis (p = .006). Measurable residual disease (MRD) negativity correlated with disease-free status outside the bone marrow, while MRD-positive cases displayed leukemic infiltrates. Infections were identified in 23 autopsied cases, notably linked to post-induction and post-transplant fatalities. Surprisingly, 18 of these 23 cases had unexpected infections mainly fungal (13 cases) with Aspergillus species as the most common. Diagnostic discrepancies were identified in 48% of cases. Malignant infiltration (46%) and infections (25%) were the leading causes of death. This research sheds light on leukemia in extra-medullary tissues, uncovers novel clinical-pathological associations, and highlights overlooked therapy side effects, offering insights for future case management.
- 1 July 2024
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 65 (11) , 1675-1690
Bridging the gap: understanding contemporary autopsies in acute leukemia by comparing ante-mortem and post-mortem profiles
This study investigates acute myeloid leukemia/lymphoblastic leukemia (AML/ALL) through a 14-year analysis (2009-2022) of 46 autopsied cases (age >12 years). B-ALL was the dominant subtype (34.8%). Liver and spleen were the common sites of active leukemia (63% cases). Symptoms like dyspnea and altered sensorium associated significantly with heart (p = .031) and brain leukostasis (p = .006). Measurable residual disease (MRD) negativity correlated with disease-free status outside the bone marrow, while MRD-positive cases displayed leukemic infiltrates. Infections were identified in 23 autopsied cases, notably linked to post-induction and post-transplant fatalities. Surprisingly, 18 of these 23 cases had unexpected infections mainly fungal (13 cases) with Aspergillus species as the most common. Diagnostic discrepancies were identified in 48% of cases. Malignant infiltration (46%) and infections (25%) were the leading causes of death. This research sheds light on leukemia in extra-medullary tissues, uncovers novel clinical-pathological associations, and highlights overlooked therapy side effects, offering insights for future case management.